| Relative performance of propensity score matching strategies for subgroup analyses SV Wang, Y Jin, B Fireman, S Gruber, M He, R Wyss, HJ Shin, Y Ma, ... American journal of epidemiology 187 (8), 1799-1807, 2018 | 75 | 2018 |
| Cardiovascular Outcomes in Patients Initiating First-Line Treatment of Type 2 Diabetes With Sodium–Glucose Cotransporter-2 Inhibitors Versus Metformin: A Cohort Study HJ Shin, S Schneeweiss, RJ Glynn, E Patorno Annals of internal medicine 175 (7), 927-937, 2022 | 38 | 2022 |
| Trends in First-Line Glucose-Lowering Drug Use in Adults With Type 2 Diabetes in Light of Emerging Evidence for SGLT-2i and GLP-1RA HJ Shin, S Schneeweiss, RJ Glynn, E Patorno Diabetes Care 44 (8), 1774-1782, 2021 | 32 | 2021 |
| A review of the performance of different methods for propensity score matched subgroup analyses and a summary of their application in peer‐reviewed research studies SV Wang, M He, Y Jin, R Wyss, HJ Shin, Y Ma, S Keeton, B Fireman, ... Pharmacoepidemiology and drug safety 26 (12), 1507-1512, 2017 | 23 | 2017 |
| Evolving channeling in prescribing SGLT‐2 inhibitors as first‐line treatment for type 2 diabetes HJ Shin, S Schneeweiss, RJ Glynn, E Patorno Pharmacoepidemiology and Drug Safety 31 (5), 566-576, 2022 | 6 | 2022 |
| High‐dose vs. standard‐dose influenza vaccine and cardiopulmonary hospitalization or mortality: emulating the INVESTED trial using insurance claims data. M NajafZadeh, HJ Shin, S Schneeweiss, SV Wang, SD Solomon, ... Clinical Pharmacology & Therapeutics, 2023 | | 2023 |
| Predicting Treatment Effects of a New‐to‐Market Drug in Clinical Practice Based on Phase III Randomized Trial Results HJ Shin, SV Wang, DH Kim, E Alt, M Mahesri, LG Bessette, ... Clinical Pharmacology & Therapeutics 114 (4), 853-861, 2023 | | 2023 |
| MSR40 Predicting Treatment Effects of a New-to-Market Drug in Clinical Practice Based on Phase III Randomized Trial Results H Shin, S Wang, DH Kim, E Alt, M Mahesri, LG Bessette, S Schneeweiss, ... Value in Health 26 (6), S285, 2023 | | 2023 |
| Predicting treatment effects of a new drug in a target population based on randomized controlled trial results H Shin, S Wang, D Kim, M Mahesri, L Bessette, JJ Gagne, S Schneeweiss, ... PHARMACOEPIDEMIOLOGY AND DRUG SAFETY 31, 17-17, 2022 | | 2022 |
| Cardiovascular outcomes of GLP-1 receptor agonists versus metformin as first-line treatment for type 2 diabetes H Shin, S Schneeweiss, R Glynn, E Patorno PHARMACOEPIDEMIOLOGY AND DRUG SAFETY 31, 333-333, 2022 | | 2022 |
| Supplement. Supplementary Materials H Shin, S Schneeweiss, RJ Glynn | | 2022 |
| Cardiovascular effectiveness of SGLT-2 inhibitors versus metformin as first-line treatment for type 2 diabetes H Shin, S Schneeweiss, R Glynn, E Patorno PHARMACOEPIDEMIOLOGY AND DRUG SAFETY 30, 42-42, 2021 | | 2021 |
| 977-P: Trends in First-Line Glucose-Lowering Drug Use in Adults with Type 2 Diabetes in Light of Emerging Evidence for SGLT2i and GLP-1RA H SHIN, S SCHNEEWEISS, R GLYNN, E PATORNO Diabetes 70 (Supplement_1), 2021 | | 2021 |
| Evolving channeling among initiators of SGLT2 inhibitors as first-line treatment for type 2 diabetes HJ Shin, S Schneeweiss, R Glynn, E Patorno PHARMACOEPIDEMIOLOGY AND DRUG SAFETY 29, 389-390, 2020 | | 2020 |
| Recent trends in first-line glucose-lowering treatment choice for type 2 diabetes in younger and older adults in the US H Shin, S Schneeweiss, R Glynn, E Patorno PHARMACOEPIDEMIOLOGY AND DRUG SAFETY 29, 254-254, 2020 | | 2020 |
| Review of Methods for Propensity Score Matched Subgroup Analysis and Their Application in Peer Reviewed Research Studies SV Wang, M He, Y Jin, R Wyss, HJ Shin, Y Ma, S Keeton, B Fireman, ... PHARMACOEPIDEMIOLOGY AND DRUG SAFETY 26, 530-530, 2017 | | 2017 |
